Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.01.1825 on September 6 2005

Journal of Clinical Oncology, Vol 23, No 28 (October 1), 2005: pp. 7013-7023
© 2005 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum (v24,p724)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Romaguera, J. E.
Right arrow Articles by Cabanillas, F. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Romaguera, J. E.
Right arrow Articles by Cabanillas, F. F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

Jorge E. Romaguera, Luis Fayad, Maria A. Rodriguez, Kristine R. Broglio, Frederick B. Hagemeister, Barbara Pro, Peter McLaughlin, Anas Younes, Felipe Samaniego, Andre Goy, Andreas H. Sarris, Nam H. Dang, Michael Wang, Virginia Beasley, L. Jeffrey Medeiros, Ruth L. Katz, Harish Gagneja, Barry I. Samuels, Terry L. Smith, Fernando F. Cabanillas

From the Departments of Lymphoma/Myeloma, Biostatistics, Cytopathology, Hematopathology, Gastroenterology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to Jorge E. Romaguera, MD, Department of Lymphoma, Unit 429, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: jromague{at}mdanderson.org

PURPOSE: To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously untreated aggressive mantle-cell lymphoma (MCL).

PATIENTS AND METHODS: This was a prospective phase II trial of rituximab plus fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD; considered one cycle) alternating every 21 days with rituximab plus high-dose methotrexate-cytarabine (considered one cycle) for a total of six to eight cycles.

RESULTS: Of 97 assessable patients, 97% responded, and 87% achieved a complete response (CR) or unconfirmed CR. With a median follow-up time of 40 months, the 3-year FFS and overall survival rates were 64% and 82%, respectively, without a plateau in the curves. For the subgroup of patients ≤ 65 years of age, the 3-year FFS rate was 73%. The principal toxicity was hematologic. Five patients died from acute toxicity. Four patients developed treatment-related myelodysplasia/acute myelogenous leukemia, and three patients died while in remission from MCL. A total of eight treatment-related deaths (8%) occurred.

CONCLUSION: Rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine is effective in untreated aggressive MCL. Toxicity is significant but expected. Because of the shorter FFS concurrent with significant toxicity in patients more than 65 years of age, this regimen is not recommended as standard therapy for this age subgroup. Larger prospective randomized studies are needed to define the role of this regimen in the treatment of MCL patients compared with existing and new treatment modalities.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
M. Wang, Y. Oki, B. Pro, J. E. Romaguera, M. A. Rodriguez, F. Samaniego, P. McLaughlin, F. Hagemeister, S. Neelapu, A. Copeland, et al.
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma
J. Clin. Oncol., November 1, 2009; 27(31): 5213 - 5218.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Ghielmini and E. Zucca
How I treat mantle cell lymphoma
Blood, August 20, 2009; 114(8): 1469 - 1476.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Hess, R. Herbrecht, J. Romaguera, G. Verhoef, M. Crump, C. Gisselbrecht, A. Laurell, F. Offner, A. Strahs, A. Berkenblit, et al.
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
J. Clin. Oncol., August 10, 2009; 27(23): 3822 - 3829.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. S. Tam, R. Bassett, C. Ledesma, M. Korbling, A. Alousi, C. Hosing, P. Kebraei, R. Harrell, G. Rondon, S. A. Giralt, et al.
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
Blood, April 30, 2009; 113(18): 4144 - 4152.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Martin, A. Chadburn, P. Christos, K. Weil, R. R. Furman, J. Ruan, R. Elstrom, R. Niesvizky, S. Ely, M. DiLiberto, et al.
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
J. Clin. Oncol., March 10, 2009; 27(8): 1209 - 1213.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Herrmann, E. Hoster, T. Zwingers, G. Brittinger, M. Engelhard, P. Meusers, M. Reiser, R. Forstpointner, B. Metzner, N. Peter, et al.
Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
J. Clin. Oncol., February 1, 2009; 27(4): 511 - 518.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Martin, M. Coleman, and J. P. Leonard
Progress in Mantle-Cell Lymphoma
J. Clin. Oncol., February 1, 2009; 27(4): 481 - 483.
[Full Text] [PDF]

Home page
 BloodHome page
C. H. Geisler, A. Kolstad, A. Laurell, N. S. Andersen, L. B. Pedersen, M. Jerkeman, M. Eriksson, M. Nordstrom, E. Kimby, A. M. Boesen, et al.
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Blood, October 1, 2008; 112(7): 2687 - 2693.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. J. Shah, L. Fayad, and J. Romaguera
Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD
Blood, September 15, 2008; 112(6): 2583 - 2583.
[Full Text] [PDF]

Home page
 BloodHome page
E. Hoster, M. Dreyling, M. Unterhalt, and for the German Low-Grade Lymphoma Study Group (GLS
Response: Statistical power and validation of the MIPI
Blood, September 15, 2008; 112(6): 2583 - 2584.
[Full Text] [PDF]

Home page
 NEJMHome page
B. D. Cheson and J. P. Leonard
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
N. Engl. J. Med., August 7, 2008; 359(6): 613 - 626.
[Full Text] [PDF]

Home page
 Ann OncolHome page
P. Martin, A. Chadburn, P. Christos, R. Furman, J. Ruan, M. A. Joyce, E. Fusco, P. Glynn, R. Elstrom, R. Niesvizky, et al.
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
Ann. Onc., July 1, 2008; 19(7): 1327 - 1330.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer
Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma
Oncologist, June 1, 2008; 13(6): 657 - 667.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Quijano, A. Lopez, A. Rasillo, S. Barrena, M. Luz Sanchez, J. Flores, C. Fernandez, J. M. Sayagues, C. S. Osuna, N. Fernandez, et al.
Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients
Blood, May 15, 2008; 111(10): 5130 - 5141.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. D. Hsi, R. Steinle, B. Balasa, S. Szmania, A. Draksharapu, B. P. Shum, M. Huseni, D. Powers, A. Nanisetti, Y. Zhang, et al.
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Clin. Cancer Res., May 1, 2008; 14(9): 2775 - 2784.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Wang, L. Zhang, X. Han, J. Yang, J. Qian, S. Hong, P. Lin, Y. Shi, J. Romaguera, L. W. Kwak, et al.
A Severe Combined Immunodeficient-hu In vivo Mouse Model of Human Primary Mantle Cell Lymphoma
Clin. Cancer Res., April 1, 2008; 14(7): 2154 - 2160.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
A. S. Perkins and J. W. Friedberg
Burkitt Lymphoma in Adults
Hematology, January 1, 2008; 2008(1): 341 - 348.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
B. S. Kahl
New Therapeutic Strategies for Mantle Cell Lymphoma
ASCO Educational Book, January 1, 2008; 2008(1): 392 - 397.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
E. Hatef, D. Roberts, P. McLaughlin, B. Pro, and B. Esmaeli
Prevalence and Nature of Systemic Involvement and Stage at Initial Examination in Patients With Orbital and Ocular Adnexal Lymphoma
Arch Ophthalmol, December 1, 2007; 125(12): 1663 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
X. Zhao, R. Lapalombella, T. Joshi, C. Cheney, A. Gowda, M. S. Hayden-Ledbetter, P. R. Baum, T. S. Lin, D. Jarjoura, A. Lehman, et al.
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical
Blood, October 1, 2007; 110(7): 2569 - 2577.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol PractHome page
D. J. Straus
How I Treat Mantle Cell Lymphoma
J. Oncol. Pract, September 1, 2007; 3(5): 281 - 282.
[Full Text] [PDF]

Home page
 ChestHome page
L. A. Robinson, J. C. Ruckdeschel, H. Wagner Jr, and C. W. Stevens
Treatment of Non-small Cell Lung Cancer-Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest, September 1, 2007; 132(3_suppl): 243S - 265S.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Wang, L. Zhang, X. Han, J. Yang, J. Qian, S. Hong, F. Samaniego, J. Romaguera, and Q. Yi
Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways
Blood, June 15, 2007; 109(12): 5455 - 5462.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. K. Gopal, J. G. Rajendran, T. A. Gooley, J. M. Pagel, D. R. Fisher, S. H. Petersdorf, D. G. Maloney, J. F. Eary, F. R. Appelbaum, and O. W. Press
High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults >= 60 Years Old With Relapsed or Refractory B-Cell Lymphoma
J. Clin. Oncol., April 10, 2007; 25(11): 1396 - 1402.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
T. A. d'Amato, R. J. Landreneau, W. Ricketts, W. Huang, R. Parker, E. Mechetner, I.-R. Yu, and J. D. Luketich
Chemotherapy resistance and oncogene expression in non-small cell lung cancer
J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 352 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F Morschhauser, S Depil, E Jourdan, M Wetterwald, R Bouabdallah, G Marit, P Solal-Celigny, C Sebban, B Coiffier, N Chouaki, et al.
Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma
Ann. Onc., February 1, 2007; 18(2): 370 - 375.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E Nitta, K Izutsu, T Sato, Y Ota, K Takeuchi, A Kamijo, K Takahashi, K Oshima, Y Kanda, S Chiba, et al.
A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study
Ann. Onc., February 1, 2007; 18(2): 364 - 369.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
Z. Sun, P. Yang, T. Singh, J. Dhindsa, J. E. Larsen, K. M. Fong, N. K. Hayward, A. Potti, D. H. Harpole Jr., and J. R. Nevins
Refining Prognosis in Non-Small-Cell Lung Cancer
N. Engl. J. Med., January 11, 2007; 356(2): 189 - 191.
[Full Text] [PDF]

Home page
 haematolHome page
P. Dreger, M. Rieger, B. Seyfarth, M. Hensel, M. Kneba, A. D. Ho, N. Schmitz, and C. Pott
Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome
Haematologica, January 1, 2007; 92(1): 42 - 49.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. I. Fisher, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al.
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
J. Clin. Oncol., October 20, 2006; 24(30): 4867 - 4874.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Kahl, W. Longo, J. Eickhoff, J Zehnder, C Jones, J Blank, T McFarland, W Bottner, H Rezazedeh, J Werndli, et al.
Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network
Ann. Onc., September 1, 2006; 17(9): 1418 - 1423.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. Potti, S. Mukherjee, R. Petersen, H. K. Dressman, A. Bild, J. Koontz, R. Kratzke, M. A. Watson, M. Kelley, G. S. Ginsburg, et al.
A Genomic Strategy to Refine Prognosis in Early-Stage Non-Small-Cell Lung Cancer
N. Engl. J. Med., August 10, 2006; 355(6): 570 - 580.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A.-M. Tsimberidou, S. O'Brien, I. Khouri, F. J. Giles, H. M. Kantarjian, R. Champlin, S. Wen, K.-A. Do, S. C. Smith, S. Lerner, et al.
Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation
J. Clin. Oncol., May 20, 2006; 24(15): 2343 - 2351.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. A. d'Amato, R. J. Landreneau, R. J. McKenna, R. S. Santos, and R. J. Parker
Prevalence of In Vitro Extreme Chemotherapy Resistance in Resected Nonsmall-Cell Lung Cancer
Ann. Thorac. Surg., February 1, 2006; 81(2): 440 - 447.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
I. F. Khouri
Reduced-Intensity Regimens in Allogeneic Stem-Cell Transplantation for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Hematology, January 1, 2006; 2006(1): 390 - 397.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online